Aim To analyse prevalence of metabolic syndrome (MS) in kidney transplant recipients at the University Clinical Centre Tuzla in Bosnia and Herzegovina (B&H), and determine effects of a modern drug therapy in achieving target metabolic control in kidney transplant patients. Methods A single-centre prospective study that included 142 kidney transplant patients over one year follow-up period was conducted. Patient data were collected during post-transplant periodical controls every 3 months including data from medical records, clinical examinations and laboratory analyses. Results Out of 142 kidney transplant patients, MS was verified in 85 (59.86%); after a pharmacologic treatment MS frequency was decreased to 75 (52.81%). After a one-year period during which patients were receiving therapy for MS, a decrease in the number of patients with hyperlipoproteinemia, decrease in average body mass index (BMI), glycemia and haemoglobin A1C (HbA1C) were observed. Hypertension did not improve during this period, which can be explained by transplant risk factors in the form of immunosuppressive drugs and chronic graft dysfunction. Conclusion A significant reduction in components of the metabolic syndrome after only one year of treatment was recorded, which should be the standard care of kidney transplant patients.
Cohen E, Korah M, Callender G, Aguiar R, Haakinson D. Metabolic Disorders with Kidney Transplantation. Clin J Am Soc Nephrol. 2020;15(Suppl 5):732–42.
2.
Hami M, Sabbagh MG, Sefidgaran A, Mojahedi MJ. Prevalence of the metabolic syndrome in kidney transplant recipients: a single-center study. Saudi J Kidney Dis Transpl. 2017;28(Suppl 2):362–7.
3.
Martin SA, Fernandez CR, Garcia GI, Aguilar MJ, Bravo SJ. Causes and components of the metabolic syndrome in renal transplant recipients from a gender perspective. Nutr Hosp. 2018;35(Suppl 5):1079–84.
4.
Dedinska I, Palkoci B, Miklusica J, Osinova D, Galajda P, Mokan M. Metabolic syndrome and new onset diabetes after kidney transplantation. Diabetes Metab Syndr. 2017;11(Suppl 3):211–4.
5.
Lee SE, Han K, Kang YM, Kim SO, Cho YK, Ko KS, et al. Trends in the prevalence of metabolic syndrome and its components in South Korea: Findings from the Korean National Health Insurance Service Database (2009-2013. PLoS One. 2018;13(Suppl 3).
6.
Nguyen TH, Daud ZA, Talib RA, R M, Poh BK. Metabolic syndrome and dietary intake are associated with quality of life in kidney transplant recipients. Transplant Proc. 2023;0041-1345 23 00563-8.
7.
Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(Suppl 3):189–230.
8.
GBDRF C. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study. Lancet. 2018;392(1923).
9.
Maasila AT, CS C, T B, N G. Prevalence, clinical profiles, and outcome of hypertension in renal transplant recipients. Indian J Transplant. 2018;12(Suppl 3):199–204.
10.
Tantisattamo E, Ho BT, Workeneh BT. Metabolic Changes After Kidney Transplantation (Editorial. Front Med. 2021;8(709644).
11.
Iannuzzo G, Cuomo G, Lorenzo A, Tripaldella M, Mallardo V, Iaccarino Idelson P, et al. Dyslipidemia in transplant patients: which therapy? J Clin Med. 2022;11(Suppl 14).
12.
Ponticelli C, Arnaboldi L, Moroni G, Corsini A. Treatment of dyslipidemia in kidney transplantation. Expert Opin Drug Saf. 2020;19(Suppl 3):257–67.
13.
Societies ESCNC. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
14.
Lin H, Yan J, Yuan L. Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data. Diabetol Metab Syndr. 2021;13(126).
15.
Hecking M, Sharif A, Eller K, Jenssen T. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transpl Int. 2021;34(Suppl 1):27–48.
16.
Ponticelli C, Favi E, Ferraresso M. New-onset diabetes after kidney transplantation. Medicina (Kaunas. 2021;57(Suppl 3).
17.
Shi B, Ying T, Xu J, Wyburn K, Laurence J, Chadban SJ. Obesity is associated with delayed graft function in kidney transplant recipients: a paired kidney analysis. Transpl Int. 2023;36(11107).
18.
Lee YH, Song SH, Song SH, Shin HS, Yang J, Kim MS, et al. Clinical implications of changes in metabolic syndrome status after kidney transplantation: a nationwide prospective cohort study.
19.
Sgambat K, Clauss S, Moudgil A. Cardiovascular effects of metabolic syndrome after transplantation: convergence of obesity and transplant-related factors. Clin Kidney J. 2018;11(Suppl 1):136–46.
20.
Jeon JY, Kim SJ, Ha KH. Trends in the effects of pretransplant diabeteson mortality and cardiovascular events afterkidney transplantation. J Diabetes Investig. 2021;12:811–8.
21.
Ahmed SH, Biddle K, Augustine T. Post-transplantation diabetes mellitus. Diabetes Ther. 2020;11(Suppl 4):779–801.
22.
Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(Suppl 5):231–7.
23.
Detection EP. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III. JAMA. 2001;285(Suppl 19):2486–97.
24.
Salvador CL, Hartmann A, Åsberg A, Bergan S, Rowe AD, Mørkrid L. Estimating glomerular filtration rate in kidney transplant recipients: comparing a novel equation with commonly used equations in this population. Transplant Direct. 2017;3(Suppl 12):332–5.
25.
Sharif A. Metabolic syndrome and solid-organ transplantation. Am J Transplant. 2010;10:12–7.
26.
Nedbalkova M, Svojanovsky J, Trnavsky K, Kuman M, Jarkovsky J, Karpisek M. Metabolic syndrome after kidney transplantation. Vnitr Lek. 2014;60(Suppl 3):196–204.
27.
Courivaud C, Kazory A, Simula D, Chalopin JM, Ducloux D. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation. 2007;83:1577–81.
28.
Hricik D. Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am Soc Nephrol. 2011;6:1781–5.
29.
Vries AP, SJ B, WJ, JJ H, RJ P, Jong PE, et al. Metabolic syndrome is associated with impaired long- term renal allograft function, not all components contribute equally. Am J Transplant. 2004;4:1675–83.
30.
Tantisattamo E, Molnar MZ, Ho BT, Reddy UG, Dafoe DC, Ichii H, et al. Approach and management of hypertension after kidney transplantation. Front Med. 2020;7(229).
31.
Bozbas H, Altin C, Karacaglar E, Kanyilmaz S, Yildirir A, Muderrisoglu H, et al. The prevalence and types of cardiovascular disease in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc. 2013;45(Suppl 10):3478–80.
32.
Mikolašević I, Jelić I, Martinović I, Orlić L, Živčić S, Vuksanović MS, et al. Metaboličke komplikacije u primatelja bubrežnog presatka (Metabolic disorders in renal transplant recipients. Croatian] Acta Med Croatica. 2012;66:235–41.
33.
Jehn U, Schütte NK, Strauss M, Kunert J, Pavenstädt H, Thölking G, et al. Antihypertensive treatment in kidney transplant recipients - a current single center experience. J Clin Med. 2020;9(Suppl 12):9.
34.
Patel DD, Modi KP, Patel AK, Chaudhary V. New onset of diabetes mellitus in Indian renal transplant recipient – a retrospective study. Int J Pharm Pharm Sci. 2015;7:228–32.
35.
Choudhury RA, Hoeltzel G, Prins K, Chow E, Moore HB, Lawson PJ, et al. Sleeve gastrectomy compared with gastric bypass for morbidly obese patients with end stage renal disease: A decision analysis. J Gastrointest Surg. 2020;24(Suppl 4):756–63.
36.
Woloszyk P, Malgorzewicz S, Chamienia A, Dębska SA. Obesity after successful kidney transplantation. Transplant Proc. 2020;52(Suppl 8):2352–6.
37.
Bellini MI, Deurloo E, Consorti F, Herbert PE. Body mass index affects kidney transplant outcomes: A cohort study over 5 years using a steroid sparing protocol. Front Endocrinol. 2023;14(1106087).
38.
AlShelleh S, AlAwwa I, Oweis A, Al Ryalat SA, AlEssa M, Saeed I, et al. Prevalence of metabolic syndrome in dialysis and transplant patients. Diabetes Metab Syndr Obes. 2019;12:575–9.
39.
Huang X, Jia Y, Zhu X, Zhang Y, Jiang L, Wei X, et al. Effects of statins on lipid profile of kidney transplant recipients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2020;2020(909454).
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
